12/3
09:36 am
lgvn
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum [Yahoo! Finance]
Low
Report
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum [Yahoo! Finance]
12/3
09:15 am
lgvn
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
Low
Report
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
12/2
09:15 am
lgvn
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
Low
Report
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
12/1
12:00 pm
lgvn
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Medium
Report
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
11/19
09:15 am
lgvn
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Medium
Report
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
11/12
09:05 am
lgvn
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Medium
Report
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
11/4
04:05 pm
lgvn
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
10/28
09:15 am
lgvn
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Low
Report
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
10/27
09:15 am
lgvn
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Low
Report
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
10/6
10:17 am
lgvn
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference [Yahoo! Finance]
Low
Report
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference [Yahoo! Finance]
10/6
09:15 am
lgvn
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Low
Report
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
10/3
03:40 pm
lgvn
Longeveron (NASDAQ:LGVN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Longeveron (NASDAQ:LGVN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
04:05 pm
lgvn
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Medium
Report
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
9/22
09:33 am
lgvn
Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa [Yahoo! Finance]
Low
Report
Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa [Yahoo! Finance]
9/22
09:15 am
lgvn
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Low
Report
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa